Newsroom | 48558 results

MATAWAN, N.J.--(BUSINESS WIRE)--(NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (“Apimeds”), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that it has merged with MindWave Innovations Inc (“MindWave”; the transaction, the “Merger”). Today, Apimeds and MindWave signed the merger agreement (the “Merger Agreement”) outlining the terms of the Merger, thus paving the way for a dual-growth enterprise spanning advanced biotechnology and institutional...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--IVI RMA North America, a leader in fertility care and assisted reproduction, today announced it has finalized a new partnership with Island Reproductive Services (“IRS” or “the Company”), the only reproductive medicine provider on Staten Island to have a fertility lab and offer comprehensive fertility treatment to its patients. The company’s partners, Dr. Eric Knochenhauer and Dr. Michael Traub, will retain an equity stake in the business and continue servi...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron’s breast cancer solutions. "Breast cancer is the most common cancer in women worldwide, and every patient's journe...

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss in patients with Meniere’s disease (MD). MD is a complex inner ear disease that involves low-to-mid frequency hearing loss, tinnitus, vertigo, and dizziness. This is the first BTD granted for the treatment of MD, for which there are no FDA approved drug treatments. Definite MD requir...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced a strategic collaboration with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, to make the OctaveⓇ Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest’s nationwide specimen-collection network. Prov...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). Caused by a mutation of the FMR1 gene, FXS is the most common inherited form of intellectual disability and autism spectrum disorder and affects an estimated 50,000 males in the U.S. and E.U. There are currently no approved therapies for t...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage genetic medicines company, today announced upcoming presentations of interim clinical data from its ongoing POLARIS Phase 1/2 open-label trials evaluating ETX101 in children with SCN1A+ Dravet syndrome. The data will be featured at the American Epilepsy Society Annual Meeting, taking place December 5–9, 2025, in Atlanta, Georgia. Dravet syndrome is a severe developmental and epileptic encephalopathy with o...

IRVING, Texas--(BUSINESS WIRE)--McKesson published its first-ever Advancing Community Oncology Report, a look at the trends influencing community oncology practices across the U.S....

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel...